Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Autor: Cannon, Cp, Pratley, R, Dagogo-Jack, S, Mancuso, J, Huyck, S, Masiukiewicz, U, Charbonnel, B, Frederich, R, Gallo, S, Cosentino, F, Shih, Wj, Gantz, I, Terra, Sg, Cherney, Dzi, Mcguire, Dk, VERTIS CV Investigators, Pugliese, G, Lembo, G

The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72aa603a4087e3dbb406ccd3293c631f
https://hdl.handle.net/11573/1474649

PATIENT-REPORTED QUALITY OF LIFE IN PATIENTS WITH BASELINE OBJECTIVE SIGNS OF INFLAMMATION AND ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS TREATED WITH GOLIMUMAB: RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY

Autor: Maksymowych, W.P., Dougados, M., Sieper, J., Braun, J., Bergman, G., Curtis, S.P., Tzontcheva, A., Philip, G., Huyck, S., Heijde, D. van der

Publikováno v: Clinical and Experimental Rheumatology, 34(4), 781-781

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::867be8ffeed10613426935a48292e3e2
https://hdl.handle.net/1887/112347

Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis after 16 Weeks of Golimumab Treatment

Autor: Maksymowych, W, Dougados, M, Sieper, J, Curtis, S, Bergman, G, Huyck, S, Tzontcheva, A

Publikováno v: 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20160831-20160903; Frankfurt am Main; DOCSP.03 /20160829/

Background: The purpose was to determine whether golimumab (GLM) is superior to placebo (PBO) in improving the Quality of Life (QoL) of patients with nonradiographic axial spondyloarthritis (nr-axSpA). Methods: GO-AHEAD was a double-blind, randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::befd72ba82bf4040d1f949ab5bbecec1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.